Biogen EV/EBIT BIIB

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2010.

Today, Oct 23, 2026: 26.3×
10-year median: 11.2×
Against its 10-year history: 90th; percentile: 0 is its lowest day, 100 its highest
10-year range: 5.6× to 31.4×
Peer median: 23.4×

Biogen's EV/EBIT is 26.3× as of Oct 23, 2026.

That is above its ten-year median of 11.2×, higher than on 90% of days in the last ten years.

Over that time it ranged from 5.6× in Jun 2020 to 31.4× in Dec 2023.

The median for 10 large drugmakers of a similar size is 23.4×.

EV/EBIT over time

median 11.2×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	26.3×	12.2×	26.3×
2025	13.0×	9.6×	13.4×
2024	12.1×	11.8×	31.4×
2023	31.4×	8.2×	31.4×
2022	8.2×	6.2×	14.9×
2021	14.9×	6.2×	19.1×
2020	6.0×	5.6×	8.2×
2019	7.7×	6.2×	11.5×
2018	10.0×	9.3×	15.0×
2017	13.0×	9.3×	14.5×
2016	11.5×	10.1×	13.2×
2015	14.1×	12.8×	27.3×
2014	22.6×	20.0×	32.4×
2013	28.4×	18.4×	29.9×
2012	18.7×	15.6×	20.5×
2011	14.9×	9.9×	16.9×
2010	10.5×	8.7×	10.7×

Against its peers

Companies in Drug Manufacturers - General nearest Biogen's size, closest first, today.

Company	EV/EBIT
BIIBBiogen	26.3×
JAZZJazz Pharmaceuticals	15.9×
BMYBristol-Myers Squibb	12.4×
BMRNBiomarin Pharmaceutical	25.8×
CORTCorcept Therapeutics	n/m
PTGXProtagonist Therapeutics	140×
TGTXTG Therapeutics	62.2×
PFEPfizer	14.5×
ALKSAlkermes plc.	69.6×
GILDGilead Sciences	23.4×
AMRXAmneal Pharmaceuticals	18.3×
Peer median	23.4×

Where Biogen ranks

#36of 48Large drugmakers with the lowest EV/EBIT

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Biogen

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.